The U.S. opioid crisis has claimed more lives than any war since World War II. It was not accidental. Purdue Pharma falsified a safety profile, paid doctors to prescribe, and made $35 billion before filing for bankruptcy. The Sackler family is still a billionaire family. Over a million Americans are dead.
Overdose deaths peaked at roughly 111,000 in 2022 -- more than gun violence and car accidents combined that year. Deaths dropped to approximately 105,000 in 2023 and fell sharply to ~80,000 in 2024, a 26.9% single-year decline -- the steepest drop in recorded history. Preliminary 2025 projections suggest roughly 71,500 deaths, continuing the trend.
The decline is real and significant. But it needs context: 71,500 deaths in a single year is still catastrophic. We are measuring progress against a crisis so severe that even massive improvement still leaves a death toll greater than the entire Vietnam War -- every single year.
Fentanyl -- a synthetic opioid 50-100 times more potent than morphine -- accounts for roughly 60% of all overdose deaths. It entered the street supply around 2016, contaminating heroin, cocaine, and eventually methamphetamine. Fentanyl-involved death rates dropped 35.6% from 2023 to 2024 -- the biggest driver of the recent decline. But a new threat is emerging: xylazine ("tranq"), a veterinary sedative not reversed by naloxone, doubled in overdose involvement between 2021 and early 2024.
The modern opioid crisis was engineered. Purdue Pharma -- owned by the Sackler family -- created a pharmaceutical product, falsified its safety profile, built a marketing machine to spread it, and bribed a medical system to prescribe it. Then they took the money and left.
OxyContin was approved by the FDA in December 1995. Purdue's pitch was that its extended-release formula made it less addictive -- a claim backed by essentially no clinical evidence. Sales grew from $48 million in 1996 to nearly $3 billion by 2001. The company doubled its sales force, flew more than 5,000 physicians to all-expenses-paid "medical education" conferences, and distributed 34,000 free starter coupons so patients could try the drug at no cost. Total OxyContin revenue exceeded $35 billion by 2017.
In 2007, Purdue pled guilty to federal criminal charges and paid $634 million in fines -- roughly eight months of revenue. The Sackler family withdrew an estimated $1.3 billion from Purdue between 1995 and 2007. Their net worth: $13 billion+. When Purdue filed for bankruptcy in 2019, total settlements had climbed. By January 2025, a new $7.4 billion settlement -- the largest with individuals in U.S. history -- was announced. Total nationwide opioid settlements now exceed $56-60 billion. Individual victims have received as little as $400-$700 after legal fees.
The political imagination of the opioid crisis is fixed on a particular image: white, suburban, prescription-addicted. That image was accurate in the crisis's early phase -- and that's precisely why it received a sympathetic policy response rather than criminalization. But the crisis has moved, and the communities now bearing the heaviest burden are not receiving the same empathy or resources.
In 2019, white Americans had the highest overdose death rate at 25.4 per 100,000. By 2023, American Indian/Alaska Native rates reached 65.0 per 100,000 and Black rates hit 48.9 -- both far exceeding the white rate of 33.1. From 1999 to 2022, overdose mortality increased 249% for Black Americans, 172% for Hispanic/Latino, and 166% for Native Americans. White Americans were the only racial group to see a statistically significant decrease in 2023.
This shift reflects geography and economics, not behavior. As prescription opioids were locked down, street drugs took over -- and street drugs are laced with fentanyl and increasingly xylazine, which naloxone cannot reverse. Communities of color with less access to emergency services, harm reduction programs, and treatment infrastructure are dying at rates that would have prompted national emergency declarations if the faces looked different.
Addiction is a medical condition. The U.S. treats it like a character flaw, a crime, or -- when it affects white communities -- a public health crisis deserving sympathy. The result: a treatment infrastructure that serves fewer than one in five people who need it.
In 2024, 48.4 million Americans had a substance use disorder. Only 10.2 million -- 19.4% -- received any treatment. Among young adults 18-25, just 11.3% who needed treatment received it. The treatment gap widened between 2023 and 2024.
Medication-Assisted Treatment (MAT) -- buprenorphine, methadone, naltrexone -- reduces overdose deaths by 50% and dramatically improves long-term recovery rates. Yet it remains deeply stigmatized. Only 6% of physicians are authorized to prescribe buprenorphine. Naloxone (Narcan) -- which reverses overdoses -- was approved over-the-counter in 2023, but costs $50+ out of pocket in many states. Harm reduction programs -- needle exchanges, fentanyl test strips, supervised consumption sites -- have the strongest evidence base of any intervention. They are being cut.